Drilldown: Medicines
Appearance
Medicines > onset
:
30–60 min
or
Postprandial glucose effect within days; HbA1c by 12 weeks
or
Sedation/dizziness within hours of oral dose; endometrial effects over days 
:
30–60 min
or
Postprandial glucose effect within days; HbA1c by 12 weeks
or
Sedation/dizziness within hours of oral dose; endometrial effects over days 
Use the filters below to narrow your results.
CNS stimulant (1) ·
NDRI (1) ·
PDE5 Inhibitor (1) ·
Psychostimulant (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (2) ·
[[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (2) ·
[[:Category:Hormone_replacement_therapy|Hormone replacement therapy]] (1) ·
[[:Category:Incretin_modulators|Incretin pathway modulator]] (2) ·
[[:Category:Progestogens|Progestogen]] (1) ·
[[:Category:Sex_hormones|Sex hormone]] (1)
None (2) ·
Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) ·
Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
'"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) ·
'"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1) ·
'"`UNIQ--vote-00000722-QINU`"', '"`UNIQ--vote-00000723-QINU`"', '"`UNIQ--vote-00000724-QINU`"', '"`UNIQ--vote-00000725-QINU`"' (1) ·
'"`UNIQ--vote-00000764-QINU`"' (1) ·
'"`UNIQ--vote-0000117B-QINU`"' (1)
None (1) ·
100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) ·
5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) ·
50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1) ·
HRT cyclic: 200 mg PO HS days 1-12 of each month; continuous: 100 mg PO daily; ART luteal support 100 mg vaginal TID or 90 mg gel daily (1)
None (1) ·
25, 50, 100 mg tablets; combination tablets with metformin (1) ·
25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1) ·
5 mg tablets; combination with metformin (1) ·
Oral 100, 200 mg capsules (peanut oil; check allergy); 100 mg vaginal insert (Endometrin); 4%, 8% vaginal gel (Crinone); IM 50 mg/mL (1)
Oral: very low (extensive first-pass); micronization improves uptake somewhat. Vaginal: high local effect with lower systemic levels (first-uterine-pass concentration)'"`UNIQ--ref-00000727-QINU`"' (1) ·
~22–25% (1) ·
~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' (1) ·
~40% (1) ·
~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1)
Showing below up to 5 results in range #1 to #5.

